Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.42 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.42 |
| ▸ | KDM6B | O15054 | 1/20 | 0.42 |
| ▸ | KDM5C | P41229 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28315095 | 0.93 | HDAC6 (0.37) | PHF8KDM2AKDM6BKDM5CEGLN1 | |
| Succinic Acid SCHEMBL28315096 | 0.88 | PHF8 (0.39) | PHF8KDM2AKDM6BKDM5CEGLN1 | |
| SCHEMBL381146 | 0.86 | HDAC6 (0.39) | PHF8KDM2AKDM6BKDM5CEGLN1 | |
| SCHEMBL23477345 | 0.81 | HDAC6 (0.39) | GBA1HDAC6HDAC1HDAC2ALDH1A1 | |
| SCHEMBL693386 | 0.80 | HDAC6 (0.40) | PHF8KDM2AKDM6BKDM5CEGLN1 | |
| SCHEMBL5884651 | 0.80 | MEN1 (0.52) | GBA1HDAC6HDAC1HDAC2PDK2 | |
| SCHEMBL1249634 | 0.78 | EPHX2 (0.43) | PHF8KDM2AHDAC6HDAC1HDAC2 | |
| SCHEMBL28909803 | 0.77 | EPHX2 (0.45) | PHF8KDM2AHDAC6HDAC1HDAC2 | |
| SCHEMBL8360181 | 0.77 | EPHX2 (0.45) | PHF8KDM2AHDAC6HDAC1HDAC2 | |
| SCHEMBL23113130 | 0.77 | EPHX2 (0.45) | PHF8KDM2AHDAC6HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416376-A1 | ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF | REGENERON PHARMA (US) | 2023-12-28 | — | — | US | disclosed |
| US-20220049001-A1 | ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. | 2022-02-17 | — | — | US | disclosed |
| EP-3927435-A1 | METHODS OF TREATING OCULAR CANCER USING ANTI-MET ANTIBODIES AND BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET | Regeneron Pharmaceuticals, Inc. (US) | 2021-12-29 | — | — | EP | disclosed |
| US-11142578-B2 | Anti-MET antibodies, bispecific antigen binding molecules that bind MET, and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2021-10-12 | — | — | US | disclosed |
| EP-3541842-A1 | ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018093866-A1 | ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| US-20180134794-A1 | ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11142578-B2 | Anti-MET antibodies, bispecific antigen binding molecules that bind MET, and methods of use thereof | MET, HGF, HGFAC | PHF8 3420/4885KDM2A 3855/4885KDM6B 3806/4885 |
| US-20220049001-A1 | ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF | MET, HGF, HGFAC | PHF8 3420/4885KDM2A 3855/4885KDM6B 3806/4885 |
| US-20230416376-A1 | ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF | MET, HGF, HGFAC | PHF8 3420/4885KDM2A 3855/4885KDM6B 3806/4885 |
| US-20180134794-A1 | ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF | MET, HGF, HGFAC | PHF8 3420/4885KDM2A 3855/4885KDM6B 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.